-
The immune response to pig-to-human kidney xenografts Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-27 Ellen F. Carney
A recent study has characterized the early immune response to xenotransplantation. The researchers used a multimodal approach to phenotype two α-1,3-galactosyltransferase-knockout pig kidney xenografts that were transplanted into brain-dead human recipients. The xenografts remained functional and produced urine throughout the 54-h study period, with no evidence of hyperacute rejection.
-
Acute kidney injury in patients with burns Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-27 Matthieu Legrand, Audra T. Clark, Javier A. Neyra, Marlies Ostermann
-
Biomolecular condensates in kidney physiology and disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-26 Guoming Gao, Emily S. Sumrall, Sethuramasundaram Pitchiaya, Markus Bitzer, Simon Alberti, Nils G. Walter
-
Gene therapy in a model of nephrotic syndrome Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-25 Susan J. Allison
Mutations in NPHS2 — which encodes the slit diaphragm protein, podocin — are the most common genetic cause of steroid-resistant nephrotic syndrome. Using genetic models of nephrotic syndrome, Ding et al. now demonstrate that adeno-associated virus (AAV)-mediated delivery of podocin can rescue defects in NPHS2.
-
The role of complement in kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-21 Vojtech Petr, Joshua M. Thurman
-
Use of kidneys from SARS-CoV-2 infected donors Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-21 Monica Wang
Transplantation of kidneys from donors with detectable SARS-CoV-2 RNA is generally deemed safe. In a new study, Miklos Molnar and colleagues investigated whether transplanting organs from deceased infected donors, including those who died from COVID-19, can affect transplant outcomes.
-
Lymph vessels, Na+ and the teleological science of hypertension Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-15 Jens M. Titze
-
Sex differences in renal transporters: assessment and functional consequences Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-08 Alicia A. McDonough, Autumn N. Harris, Lingyun (Ivy) Xiong, Anita T. Layton
-
Interorgan communication networks in the kidney–lung axis Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-09-04 Yohei Komaru, Yun Zhu Bai, Daniel Kreisel, Andreas Herrlich
-
Designing acute kidney injury clinical trials Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-31 Alexander Zarbock, Lui G. Forni, Marlies Ostermann, Claudio Ronco, Sean M. Bagshaw, Ravindra L. Mehta, Rinaldo Bellomo, John A. Kellum
-
Digital determinants of health: opportunities and risks amidst health inequities Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-25 Jack Gallifant, Leo Anthony Celi, Robin L. Pierce
Digital transformation offers unprecedented opportunities for advancing healthcare, but also raises complex ethical and legal challenges. Emerging drivers of health disparity termed ‘digital determinants of health’ call for purposeful, equity-focused strategies to ensure that technological innovation benefits all without exacerbating disparities.
-
Primary aldosteronism: molecular medicine meets public health Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-23 Elena A. B. Azizan, William M. Drake, Morris J. Brown
-
Diagnosis of cardiovascular disease in patients with chronic kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-23 Carmine Zoccali, Patrick B. Mark, Pantelis Sarafidis, Rajiv Agarwal, Marcin Adamczak, Rodrigo Bueno de Oliveira, Ziad A. Massy, Peter Kotanko, Charles J. Ferro, Christoph Wanner, Michel Burnier, Raymond Vanholder, Francesca Mallamaci, Andrzej Wiecek
-
RNA interference for treatment of hypertension Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-23 Ellen F. Carney
New data from a phase 1 clinical trial suggest that the small-interfering RNA (siRNA) therapeutic zilebesiran could be beneficial in patients with hypertension. Zilebesiran is designed to specifically inhibit the hepatic production of angiotensinogen, which is the precursor of all angiotensin peptides.
-
Targeting IL-1Ra to attenuate fungal infection Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-22 Monica Wang
IL-1 receptor antagonist (IL-1Ra) secreted by macrophages might be a therapeutic target in invasive fungal sepsis, according to a study by Stefan Freigang and colleagues.
-
Role of perivascular cells in kidney homeostasis, inflammation, repair and fibrosis Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-22 Shinji Tanaka, Didier Portilla, Mark D. Okusa
-
The realities of diagnosing and managing glomerular disease in low-income countries Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-18 Robert Kalyesubula
The diagnosis of glomerular disease relies largely on meticulous histological and laboratory investigations that continue to improve with technological advances. However, low-income countries such as Uganda lack this investigatory armamentarium and patients are often treated on the basis of suboptimal evidence.
-
Impact of persistent conflict and destabilizing events on dialysis care Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-16 Sami Alasfar, Ephrem Berhe, Sabine Karam, Valerie Luyckx
Among global destabilizing events, natural disasters often receive widespread attention whereas protracted conflicts and economic crises fade into the background. Low- and middle-income countries bear the brunt of this indifference, resulting in severely weakened health systems. People who require dialysis are particularly vulnerable, necessitating urgent collaboration to ensure equitable and sustainable
-
Propagation of acute kidney injury Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-15 Susan J. Allison
Acute kidney injury (AKI) triggers remodelling of the tubule epithelium; however, insights into the dynamics of this process are limited. Using serial intravital two-photon microscopy to track tissue remodelling in a model of partial ischaemia–reperfusion injury, Luca Bordoni and colleagues now show that injury propagates along the nephron and can predict tubule atrophy.
-
Inequities in kidney health and kidney care Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-14 Raymond Vanholder, Lieven Annemans, Marion Braks, Edwina A. Brown, Priya Pais, Tanjala S. Purnell, Simon Sawhney, Nicole Scholes-Robertson, Bénédicte Stengel, Elliot K. Tannor, Vladimir Tesar, Arjan van der Tol, Valérie A. Luyckx
-
Digital health and acute kidney injury: consensus report of the 27th Acute Disease Quality Initiative workgroup Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-14 Kianoush B. Kashani, Linda Awdishu, Sean M. Bagshaw, Erin F. Barreto, Rolando Claure-Del Granado, Barbara J. Evans, Lui G. Forni, Erina Ghosh, Stuart L. Goldstein, Sandra L. Kane-Gill, Jejo Koola, Jay L. Koyner, Mei Liu, Raghavan Murugan, Girish N. Nadkarni, Javier A. Neyra, Jacob Ninan, Marlies Ostermann, Neesh Pannu, Parisa Rashidi, Claudio Ronco, Mitchell H. Rosner, Nicholas M. Selby, Benjamin Shickel
-
Increasing diversity and inclusion in nephrology clinical trials Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-07 Bessie A. Young, Sylvia E. Rosas
-
Reducing preventable acute kidney injury in a hospital setting Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-08-01 Rolando Claure-Del Granado
Acute kidney injury (AKI) is a global concern that affects patient outcomes and resource utilization. An effective educational programme aimed at improving early AKI identification, triaging and treatment, using risk scores and care bundles coupled with access to point-of-care diagnostics, can help to prevent AKI-related deaths in regions with limited resources.
-
Immune-checkpoint inhibition to slow cyst growth Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-31 Monica Wang
Autosomal dominant polycystic kidney disease (ADPKD) is associated with innate and adaptive immune alterations. Now, Katharina Hopp and colleagues suggest that immune-checkpoint inhibition could slow the progression of ADPKD.
-
The genetics and pathogenesis of CAKUT Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-31 Caroline M. Kolvenbach, Shirlee Shril, Friedhelm Hildebrandt
-
Cryopreservation breaks the organ transplant time barrier Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-28 Marlon J. A. de Haan, Ton J. Rabelink
-
Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-27 Alla Mitrofanova, Sandra Merscher, Alessia Fornoni
-
Urinary CXCL9: a biomarker for AIN Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-27 Susan J. Allison
Early identification of acute interstitial nephritis (AIN) can enable withdrawal of the causative drug or initiation of therapy; however, methods to differentiate AIN from other forms of acute kidney injury (AKI) are limited and often requires a kidney biopsy. In new research, Dennis Moledina and colleagues identify and validate CXCL9 as a diagnostic biomarker for AIN, which they say may reduce the
-
Historical redlining and kidney failure Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-26 Ellen F. Carney
Kevin Nguyen and colleagues investigated the association between residence in historically redlined areas and kidney failure in 2012–2019. They report a significantly higher incidence of kidney failure in redlined areas (Home Owners Loan Corporation (HOLC) grade D; 740.7 per million) than in areas with the best HOLC grade (HOLC grade A; 326.5 per million). Among Black adults, the kidney failure incidence
-
GFR slope as a surrogate marker for future kidney failure Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-26 Jennifer S. Lees, Patrick B. Mark
-
Inflammation and gut dysbiosis as drivers of CKD–MBD Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-24 Pieter Evenepoel, Peter Stenvinkel, Catherine Shanahan, Roberto Pacifici
-
Uropathogen and host responses in pyelonephritis Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-21 Laura Schwartz, Juan de Dios Ruiz-Rosado, Emily Stonebrook, Brian Becknell, John David Spencer
-
Disasters and kidney care: pitfalls and solutions Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-21 Mehmet Sukru Sever, Valerie Luyckx, Marcello Tonelli, Rumeyza Kazancioglu, Darlene Rodgers, Dani Gallego, Serhan Tuglular, Raymond Vanholder
-
Aquaporin water channels: roles beyond renal water handling Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-17 Frédéric H. Login, Lene N. Nejsum
-
Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-12 Carola G. Vinuesa, Nan Shen, Thuvaraka Ware
-
Regulatory T cells in autoimmune kidney diseases and transplantation Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-07-03 Norihisa Mikami, Shimon Sakaguchi
-
Indian Hedgehog links kidney injury to fibrosis Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-06-29 Susan J. Allison
Kidney injury can induce organ fibrosis through the proliferation and activation of GLI1-expressing mesenchymal cells; however, the mechanism that links injury to GLI1 activation is unclear. Now, researchers show that leukocyte-derived TNF promotes GLI1+ cell proliferation and fibrosis through the induction and release of Indian Hedgehog (IHH) from tubule epithelial cells.
-
Beyond state borders: transforming dialysis care for undocumented immigrants Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-06-28 Devon Cassidy, Katie Rizzolo, Neil R. Powe, Lilia Cervantes
-
Canagliflozin disrupts T cell activation Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-06-27 Monica Wang
Autoreactive T cell function is an important therapeutic target in autoimmunity and a study by Nicholas Jones and colleagues now suggests that the sodium–glucose co-transporter 2 (SGLT2) inhibitor canagliflozin (cana) could be used to modulate T cell activation.
-
CONVINCE trial reports a survival benefit of haemodiafiltration compared with haemodialysis Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-06-26 Ellen F. Carney
New data from the CONVINCE open-label, randomized controlled trial show a lower risk of death among patients with kidney failure who were receiving high-dose haemodiafiltration than among those who were receiving conventional high-flux haemodialysis. These results were presented at the 60th ERA congress in Milan and published in the New England Journal of Medicine.
-
The role of claudins in homeostasis Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-06-21 Luca Meoli, Dorothee Günzel
-
Circulating non-coding RNAs in chronic kidney disease and its complications Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-06-07 Anton Jan van Zonneveld, Qiao Zhao, Joris I. Rotmans, Roel Bijkerk
-
Portable, wearable and implantable artificial kidney systems: needs, opportunities and challenges Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-06-05 David Loureiro Ramada, Joost de Vries, Jeroen Vollenbroek, Nazia Noor, Odyl ter Beek, Silvia M. Mihăilă, Fokko Wieringa, Rosalinde Masereeuw, Karin Gerritsen, Dimitrios Stamatialis
-
Dysfunctional UCH-L1 inhibits proteostasis Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-05-31 Monica Wang
Podocyte injury in membranous nephritis (MN) is associated with induction of the ubiquitin proteasome system. Meyer-Schwesinger and colleagues previously reported de novo expression of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in MN and now show a link between dysfunctional UCH-L1 and impaired podocyte proteostasis.
-
Chronic kidney disease promotes ageing in a multiorgan disease network Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-05-26 Thomas Benzing, Björn Schumacher
-
Pathogenic cellular and molecular mediators in lupus nephritis Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-05-24 Chandra Mohan, Ting Zhang, Chaim Putterman
-
The kidney is a novel target of metformin Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-05-17 Ellen F. Carney
Zhang and colleagues found that infusion of metformin compared with saline reduced food intake and weight gain upon refeeding in male rats fed a high-fat diet (HFD). In addition, metformin increased the plasma levels of growth/differentiation factor 15 (GDF15) and upregulated kidney GDF15 expression in these rats. Kidney-specific knockdown of GDF15 in HFD-fed rats significantly reduced the metformin-induced
-
Identification of erythropoietin-producing cells Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-05-15 Susan J. Allison
The endocrine hormone erythropoietin (Epo) is produced in the kidney under hypoxic conditions; following its secretion it binds to erythroid progenitors in the bone marrow to induce erythropoiesis. However, the cells responsible for Epo production have not been characterized. New findings identify a distinct population of kidney stromal cells, termed Norn cells, as the major source of Epo production
-
Pathogenesis of autoimmune disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-05-10 David S. Pisetsky
-
Mannose as a driver of γδ T cell kidney infiltration Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-05-02 Monica Wang
Aberrant glycosylation has been implicated in autoimmune diseases, and high expression of mannose in the kidney might contribute to lupus nephritis (LN) by promoting γδ T cell infiltration, according to a study by Salomé Pinho and colleagues.
-
Key role of α-synuclein in Fabry nephropathy Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-05-02 Ellen F. Carney
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene. These mutations result in impaired activity of the encoded enzyme, α-galactosidase A, and subsequent intracellular accumulation of its substrate globotriaosylceramide (Gb3). However, the mechanisms that underlie Fabry nephropathy are not well understood. Now, Tobias Huber and coauthors report that accumulation
-
Inaxaplin for the treatment of APOL1-associated kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-04-27 Rasheed Gbadegesin, Brandon Lane
APOL1 risk variants are associated with an increased risk of chronic kidney disease. Findings from a new study demonstrate that a small molecule, inaxaplin, inhibits APOL1 channel function; furthermore, inaxaplin reduced proteinuria in patients with focal segmental glomerulosclerosis and two APOL1 risk variants.
-
Interim analysis indicates sparsentan PROTECTs in IgAN Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-04-20 Susan J. Allison
Patients with IgA nephropathy (IgAN) and proteinuria of 1 g per day or greater are at risk of kidney disease progression. New findings from a prespecified interim analysis of the PROTECT trial, presented at the World Congress of Nephrology 2023 and published in the Lancet, demonstrate that the dual endothelin and angiotensin receptor antagonist, sparsentan, has greater antiproteinuric effects than
-
Intersectionality as a lens for achieving kidney health justice Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-04-20 Elle Lett, Carmen H. Logie, Dinushika Mohottige
Individuals who are members of multiple marginalized populations experience multiple axes of oppression and discrimination. Such intersectional discrimination can have interactive, negative effects on all aspects of life, including health. To achieve health equity, intersectional-discrimination-induced kidney harms must be examined, measured and mitigated.
-
Menopause and chronic kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-04-19 Virginia A. Dines, Vesna D. Garovic
-
Mentorship in the lives of scholars Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-04-19 Isi Ero-Tolliver
Mentoring is an essential component of scientific leadership and can have a profound impact on the development and life course of the mentee. Isi Ero-Tolliver, Dean of the School of Science at Hampton University, describes the life-changing and long-lasting effects of mentorship and why it is important to invest time and effort in mentoring.
-
The importance of sex and gender in basic and clinical research Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-04-17 Sofia B. Ahmed
The importance of incorporating factors related to sex and gender in all aspects of research is increasingly recognized. Kidney disease pathophysiology, presentation, response to therapy and outcomes differ by sex and gender, but these factors are often not considered in basic and clinical studies. It is time for nephrology to catch up.
-
Considerations in the care of transgender persons Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-04-17 Sofia B. Ahmed, Lauren B. Beach, Joshua D. Safer, Jaimie F. Veale, Cameron T. Whitley
Transgender persons can face a number of barriers in accessing primary and specialist care that is equitable, inclusive and appropriate for their needs. In this Viewpoint, commissioned to recognize Pride, five researchers with expertise across different disciplines, including nephrology, endocrinology, public health, psychology and sociology, provide their perspectives on key considerations that are
-
Complosome — the intracellular complement system Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-04-13 Erin E. West, Claudia Kemper
-
The roles of tertiary lymphoid structures in chronic diseases Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-04-12 Yuki Sato, Karina Silina, Maries van den Broek, Kiyoshi Hirahara, Motoko Yanagita